The analyses also identified individuals who had a family history of Alzheimer's disease and individuals who were APOE ε4 carriers as having a decreased odds of trial dropout of 25% and 21% respectively; though these associations were only marginally significant. The gene discussed is APOE; the disease is Alzheimer disease.